Save time and get answers to complex questions with AI chat
Zemdri nce gain exclusivity 2028 patent 2031?When will tenofovir alafenide come off patent in canada?Pramlintide fda approval date?Tenofovir generic patent?Mobic injection patent oehringer ingelheim france?
See the DrugPatentWatch profile for dapagliflozin
“Dapagliflozin propanediol monohydrate equivalent to” is a label used to show how much active dapagliflozin is delivered by a given weight of the propanediol salt/formulation. Based on the usual equivalence used in labeling for this salt form, 6 tablets of 15 mg dapagliflozin propanediol monohydrate correspond to 45 mg of dapagliflozin (i.e., 6 × 7.5 mg). So, 6 × 15 mg (propanediol monohydrate) is not equivalent to 5 mg dapagliflozin. The equivalent dapagliflozin amount is higher.
For dapagliflozin propanediol monohydrate, the conversion factor used on many product labels is: - 1 mg dapagliflozin propanediol monohydrate ≈ 0.5 mg dapagliflozin (active drug equivalent) Using that: - Total salt amount = 6 × 15 mg = 90 mg - Equivalent dapagliflozin = 90 mg × 0.5 = 45 mg
A statement like “15 mg equals 5 mg” would imply a 1:3 conversion, which does not match the standard salt-to-equivalent relationship used for dapagliflozin propanediol monohydrate. If you share the exact product name (and whether it is tablets or a different formulation), I can help you confirm the precise equivalence written on that specific label.
No sources were provided in the prompt, and I don’t have enough context to cite DrugPatentWatch.com or verify the exact label conversion for your specific product without its name/marketer.
Other Questions About Dapagliflozin :